CRISPR Therapeutics Stock News

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medic

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The health sector has two things to offer: new ideas and consistent returns. As a result, healthcare stocks will continue to be a good choice for investors looking for growth opportunities in 2024.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $70.01, moving +1.71% from the previous trading session.

CRISPR Therapeutics recently reached a major milestone: the approval of its first product. Teladoc Health is taking steps to optimize efficiency and travel the path to profitability.

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $64.75, denoting a +0.12% change from the preceding trading day.

Healthcare stocks are one part of the stock market that has a lot of room to grow until 2024. The healthcare industry is growing because of the growing focus on health and well-being around the world

CRISPR Therapeutics recently won approval for its first product, a potential blockbuster. The company expects to report clinical trial data from its immuno-oncology program this year.

With the recent uptrend in large-cap stocks, as reflected by the performance of the SPDR S&P 500 ETF Trust NYSEARCA: SPY, many stocks with top revenue and earnings growth rates are flashing bullish te

CRISPR Therapeutics' leading candidate recently received regulatory approval. This gene-editing therapy stands to improve the biotech's financial results.

CRISPR Therapeutics just had its biggest collaborator pull out of a joint program. At the same time, management is cruising for business development opportunities.

Gene therapy will get its share of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. NASDAQ: VRTX and CRISPR Therapeutics AG NASDAQ: CRSP CR

CRISPR Therapeutics reached three milestones in recent times and is on its way to product revenue. The biotech company is also making progress with other pipeline programs based on its cutting-edge ge

Editas Medicine is a gene-editing biotech, just like CRISPR Therapeutics. Editas has a long way to go before it'll be self-sustaining, and it might not get there.

Intellia Therapeutics is well capitalized, and moving into late-stage clinical trials. CRISPR Therapeutics will be raking in revenue and likely launching another therapy.